MarketPulse
H

$HCM

3 articles found
2 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Advances Cancer Pipeline with Phase III HMPL-760 Trial Launch

HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory lymphoma in China, enrolling 240 patients following positive Phase II results.
HCMclinical developmentoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Reshuffles Board Leadership as Veteran Director Steps Down

HUTCHMED announces retirement of independent director after 8+ years, triggering board committee restructuring with new senior independent director appointment.
HCMcorporate governanceBoard composition
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Launches Global Trial for Dual-Action Tumor Therapy HMPL-A580

HUTCHMED initiates Phase I/IIa trial of HMPL-A580, a novel antibody-targeted therapy combining PI3K/PIKK inhibitor with anti-EGFR antibody for solid tumors across China and US.
HCMclinical developmentsolid tumors